The REPRIEVE trial focuses on developing a cardiovascular disease prevention strategy for individuals living with HIV. It addresses the increased risk of CVD in this population, even with good viral suppression. The study evaluates the use of pitavastatin, a statin with anti-inflammatory properties,

1 views • 33 slides

This study led by Dr. Steven E. Nissen explores a novel Web Application aimed at helping consumers qualify for nonprescription access to rosuvastatin (5 mg) based on their ASCVD risk scores. The application features innovative eligibility criteria and outcomes, filling a gap in providing statin trea

0 views • 20 slides

This guideline outlines the management of blood cholesterol in high-risk groups according to the 2018 ACC/AHA recommendations. It discusses the overall approach, different statin management groups, justification for statin use in high-risk populations, high and moderate-intensity statin therapy, and

1 views • 14 slides

Lipid management in secondary prevention plays a crucial role in reducing cardiovascular risk. This study led by Dr. Timir Paul aims to address system-level gaps in care, enhance communication for optimal therapy, and empower patients in achieving target lipid levels. By recognizing disparities and

0 views • 28 slides